Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma

BACKGROUND: Multiple myeloma survival rates are steadily increasing due to availability of new drug classes used in combination with corticosteroids and chemotherapy. The latest treatments are daratumumab or bortezomib in combination therapy with lenalidomide and dexamethasone (Rd). Daratumumab, a C...

Descripción completa

Detalles Bibliográficos
Autores principales: Narsipur, Nihal, Bulla, Sabrina, Yoo, Connie, Do, Brenda, Tran, Kyle, Gu, Dian, Zhong, Lixian, Wilson, Leslie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391124/
https://www.ncbi.nlm.nih.gov/pubmed/34818089
http://dx.doi.org/10.18553/jmcp.2021.27.12.1691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391124/
https://www.ncbi.nlm.nih.gov/pubmed/34818089
http://dx.doi.org/10.18553/jmcp.2021.27.12.1691

Ejemplares similares